Under the agreement with Royalty Pharma, the companies will jointly develop the anti-IL-15 antibody, TEV-'408, which is in a ...

Teva and Royalty Pharma have signed a deal worth up to $500 million to advance TEV-408, a drug being tested for vitiligo and ...

Teva Pharmaceuticals TEVA announced a funding agreement with Royalty Pharma plc RPRX, under which the latter will provide up ...

Royalty funding market reached record high of $10 billion in 2025, powered by synthetic royalties Royalty Pharma maintained industry leadership ...

Teva has penned a second pact with Royalty Pharma, this time securing up to $500 million to support the clinical development ...

Royalty Pharma to provide up to $500 million, including $75 million for Phase 2b funding and a Royalty Pharma option for an additional $425 ...

Royalty Pharma's board has raised the biopharmaceutical royalties investor's quarterly dividend by 6.8%, to 23.5 cents from 22 cents. The new payout, equal to 94 cents a year, represents an annual ...

The end of the earnings season is always a good time to take a step back and see who shined (and who not so much). Let’s take ...

Xoma argued Janssen breached the contract Xoma had with the third-party pharmaceutical company, as well as the contract the ...

Royalty Pharma Evrysdi royalty acquisition completed for $240M. RPRX now owns 100% of the tiered royalty on Roche's SMA drug, ...

Royalty Pharma has acquired PTC's remaining royalty on Roche's Evrysdi for $240 million upfront and sales-based milestones.

NEW YORK – Royalty Pharma has acquired the remaining royalty interest of PTC Therapeutics in Roche's spinal muscular atrophy drug Evrysdi (risdiplam) for up to $300 million, the company announced ...